Cerebrospinal fluid and plasma concentrations of morphine, morphine-3- glucuronide, and morphine-6-glucuronide in patients before and after initiation of intracerebroventricular morphine for cancer pain management

Anesthesia and Analgesia

Volumn 88, Issue 1, 1999, Pages 109-116

  Smith, Maree T ^b   Wright, Andrew W E ^c   Williams, Bronwyn E ^a   Stuart, Gordon ^a   Cramond, Tess ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE;

ADULT; AGED; ANALGESIA; ANASTOMOSIS; ARTICLE; CANCER PAIN; CANCER PATIENT; CLINICAL ARTICLE; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DETERMINATION; DRUG TOLERANCE; FEMALE; HUMAN; HYPERALGESIA; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; MYOCLONUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SEIZURE; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANALGESICS, OPIOID; FEMALE; HUMANS; INDIVIDUALITY; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MORPHINE; MORPHINE DERIVATIVES; NEOPLASMS; PAIN;

EID: 0032958695     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199901000-00021     Document Type: Article

References (28)

1. Obbens EA, Hill CS, Leavens ME, et al. Intraventricular morphine administration for control of chronic cancer pain. Pain 1987;28:61-8.
2. Lazorthes Y. Intracerebroventricular administration of morphine for control of irreducible cancer pain. Ann N Y Acad Sci 1988;531:123-32.
3. Cramond T, Stuart G. Intraventricular morphine for intractable pain of advanced cancer. J Pain Symptom Manage 1993;8: 465-73.
4. Karavelis A, Foroglou G, Selviaridis P, Fountzilas G. Intraventricular administration of morphine for control of intractable cancer pain in 90 patients. Neurosurgery 1996;39:57-61.
5. Ballantyne JC, Carr DB, Berkey CS, et al. Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer. Reg Anesth 1996,21:514-6.
6. Milne RW, Nation RL, Somogyi AA. The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab Rev 1996;28:345-472.
7. Labella FS, Pinsky C, Havlicek V. Morphine derivatives with diminished opiate receptor potency show enhanced central excitatory activity. Brain Res 1979;174:263-71.
8. Smith MT, Watt JA, Cramond T. Morphine-3-glucuronide: a potent antagonist of morphine analgesia. Life Sci 1990;47: 579-85.
9. A receptor complex. Life Sci 1994;54:687-94.
10. Sjogren P, Jonsson T, Jensen NH, et al. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain 1993;55:93-7.
11. Gong QL, Hedner J, Bjorkman R, Hedner T. Morphine-3-glucuronide may functionally antagonise morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain 1992;48:249-55.
12. Faura CC, Olaso MJ, Garcia-Cabanes C, Horga JF. Lack of morphine-6-glucuronide antinociception after morphine treatment: is morphine-3-glucuronide involved? Pain 1996;65: 25-30.
13. Hewett K, Dickenson AH, McQuay HJ. Lack of effect of morphine-3-glucuronide on the spinal antinociceptive actions of morphine in the rat: an electrophysiological study. Pain 1993; 53:59-63.
14. Suzuki N, Kalso E, Rosenberg PJ. Intrathecal morphine-3-glucuronide does not antagonize spinal antinociception by morphine or morphine-6-glucuronide in rats. Eur J Pharmacol 1993; 249:247-50.
15. Cramond T. Invasive techniques for neuropathic pain. In: Portenoy RK, Bruera E, eds. Topics in palliative care. vol. 2. New York: Oxford University Press, 1998:63-86.
16. Wright AWE, Watt JA, Kennedy M, et al. Quantitation of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid using solid-phase extraction and high-performance liquid chromatography with electrochemical detection. Ther Drug Monit 1994;6:200-8.
17. Goucke CR, Hackett LP, Ilett KF. Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide in serum and cerebrospinal fluid after morphine administration to patients with morphine-resistant pain. Pain 1994;56:145-9.
18. Shen KF, Crain SM, Dual opioid modulation of the action potential duration of mouse dorsal root ganglion neurons in culture. Brain Res 1989;491:227-42.
19. Sutters KA, Miaskowski C, Taiwo YO, Levine JD. Analgesic synergy and improved motor function produced by combinations of mu-delta and mu-kappa opioids. Brain Res 1990;530: 290-4.
20. Yeung JC, Rudy TA. Multiplicative interaction between narcotic agonisms expressed at spinal and supraspinal sites of antinociceptive action as revealed by concurrent intrathecal and intracerebroventricular injections of morphine. J Pharmacol Exp Ther 1980;215:633-42.
21. Hanks GW, Hoskin PJ, Aherne GW, et al. Explanation for potency of repeated oral doses of morphine? Lancet 1986;2:723-5.
22. Gong QL, Hedner T, Hedner J, et al. Antinociceptive and ventilatory effects of the morphine metabolites: morphine-6-glucuronide and morphine-3-glucuronide. Eur J Pharmacol 1991;193:47-56.
23. Pelligrino DA, Riegler FX, Albrecht RF. Ventilatory effects of fourth cerebroventricular infusions of morphine-6-or morphine-3-glucuronide in the awake dog. Anesthesiology 1989;71:936-40.
24. Paul D, Standifer KM, Inturrisi CE, Pasternak GW. Pharmacological characterization of morphine-6β-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther 1989;251: 477-83.
25. Smith GD, Smith MT. Morphine-3-glucuronide: evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in the rat. Pain 1995;62: 51-60.
26. Barjavel MJ, Scherrmann JM, Bhargava HN. Relationship between morphine analgesia and cortical extracellular fluid levels of morphine and its metabolites in the rat: a microdialysis study. Br J Pharmacol 1995;116:3205-10.
27. Lipkowski AW, Carr DB, Langlade A, et al. Morphine-3-glucuronide: silent regulator of morphine actions. Life Sci 1994; 55:149-54.
28. Ouellet DM, Pollack GM. Effect of prior morphine-3-glucuronide exposure on morphine disposition and antinociception. Biochem Pharmacol 1997;53:1451-7.